From: The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis
a Before propensity matching | |||
Factor | HR | 95%CI | P value |
GC type | Â | Â | Â |
 non-HAS | - | - | - |
 HAS | 1.193 | 0.596 -2.386 | 0.619 |
Age (yr) | Â | Â | 0.463 |
 <45 | - | - | - |
 60>age≥45 | 1.113 | 0.621-1.993 | 0.720 |
 ≥60 | 1.335 | 0.752-2.372 | 0.324 |
Location | Â | Â | 0.978 |
 U | - | - | - |
 M | 1.000 | 0.628-1.594 | 0.999 |
 L | 1.031 | 0.573-1.857 | 0.918 |
 T | 1.304 | 0.392-4.334 | 0.665 |
Surgery type | Â | Â | 0.152 |
 PG | - | - | - |
 DG | 1.096 | 0.137-8.782 | 0.931 |
 TG | 1.805 | 0.242-13.456 | 0.564 |
 TGC | 4.924 | 0.407-59.619 | 0.210 |
Vascular invasion | Â | Â | Â |
 no | - | - |  |
 yes | 1.145 | 0.771-1.701 | 0.503 |
T | Â | Â | <0.001 |
 Tis,T0,T1,T2 | - | - | - |
 T3 | 1.930 | 0.939-3.967 | 0.074 |
 T4 | 3.518 | 1.756-7.050 | <0.001 |
N | Â | Â | 0.001 |
 N0 | - | - | - |
 N1 | 1.945 | 0.983-3.847 | 0.056 |
 N2 | 2.133 | 1.070-4.252 | 0.031 |
 N3 | 3.579 | 1.839-6.966 | <0.001 |
CEA (ng/ml) | Â | Â | Â |
 ≤5 | - | - | - |
 >5 | 1.460 | 0.992-2.151 | 0.055 |
CA199 (u/ml) | Â | Â | Â |
 ≤37 | - | - | - |
 >37 | 1.514 | 0.998-2.297 | 0.051 |
EGFR | Â | Â | 0.046 |
 - | - | - | - |
 + | 1.342 | 0.788-2.286 | 0.279 |
 ++ | 0.766 | 0.399-1.468 | 0.422 |
 +++ | 0.786 | 0.411-1.503 | 0.467 |
Neoadjuvant chemotherapy | |||
 no | - | - | - |
 yes | 1.724 | 1.123-2.646 | 0.013 |
b After 1:1 propensity matching | |||
Factor | HR | 95%CI | P |
GC type | Â | Â | Â |
 non-HAS | - | - | - |
 HAS | 1.114 | 0.390-3.183 | 0.841 |
Age (yr) | Â | Â | 0.158 |
 <45 | - | - | - |
 60>age≥45 | 1.103 | 0.120-10.169 | 0.931 |
 ≥60 | 2.716 | 0.322-22.934 | 0.359 |
Vascular invasion | |||
 no | - | - | - |
 yes | 4.633 | 0.936-22.942 | 0.060 |
T | Â | Â | 0.049 |
 Tis,T0,T1,T2 | - | - | - |
 T3 | 3.779 | 0.674-21.186 | 0.131 |
 T4 | 8.435 | 1.408-50.544 | 0.020 |
N | Â | Â | 0.241 |
 N0 | - | - | - |
 N1 | 0.113 | 0.014-0.921 | 0.042 |
 N2 | 0.233 | 0.033-1.668 | 0.147 |
 N3 | 0.198 | 0.024-1.659 | 0.136 |
M | |||
 M0 | - | - | - |
 M1 | 7.354 | 1.760-30.737 | 0.006 |
CEA (ng/ml) | |||
 ≤5 |  |  |  |
 >5 | 3.123 | 1.276-7.643 | 0.013 |
CA199 (u/ml) | |||
 ≤37 |  |  |  |
 >37 | 4.275 | 0.759-24.071 | 0.099 |
EGFR | Â | Â | 0.030 |
 - | - | - | - |
 + | 0.115 | 0.010-1.347 | 0.085 |
 ++ | 0.028 | 0.002-0.375 | 0.007 |
 +++ | 0.101 | 0.009-1.159 | 0.066 |
Neoadjuvant chemotherapy | |||
 no | - | - | - |
 yes | 3.816 | 1.339-10.878 | 0.012 |
c After 1:2 propensity matching | |||
Factor | HR | 95%CI | P |
GC type | |||
 non-HAS | - | - | - |
 HAS | 2.579 | 0.839-7.925 | 0.098 |
Age (yr) | Â | Â | 0.306 |
 <45 | - | - | - |
 60>age≥45 | 5.503 | 0.159-190.915 | 0.346 |
 ≥60 | 9.580 | 0.304-301.867 | 0.199 |
Vascular invasion | |||
 no | - | - | - |
 yes | 2.597 | 0.472-14.281 | 0.273 |
T | Â | Â | 0.207 |
 Tis,T0,T1,T2 | - | - | - |
 T3 | 5.591 | 0.775-40.367 | 0.088 |
 T4 | 6.032 | 0.732-49.721 | 0.095 |
N | Â | Â | 0.640 |
 N0 | - | - | - |
 N1 | 0.637 | 0.072-5.636 | 0.685 |
 N2 | 0.355 | 0.036-3.515 | 0.376 |
 N3 | 0.912 | 0.111-7.474 | 0.932 |
M | |||
 M0 | - | - | - |
 M1 | 51.522 | 2.359-1125.341 | 0.012 |
CEA (ng/ml) | Â | Â | - |
 ≤5 | - | - |  |
 >5 | 8.116 | 2.294-28.719 | 0.001 |
CA199 (u/ml) | |||
 ≤37 |  |  |  |
 >37 | 0.000 | 0.000- | 0.983 |
EGFR | Â | Â | 0.214 |
 - | - | - | - |
 + | 0.150 | 0.014-1.587 | 0.115 |
 ++ | 0.094 | 0.009-0.929 | 0.043 |
 +++ | 0.136 | 0.019-0.996 | 0.050 |
Neoadjuvant chemotherapy | |||
 no | - | - | - |
 yes | 2.717 | 0.729-10.131 | 0.137 |